Lv1
20 积分 2022-07-21 加入
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study
4小时前
待确认
Bleeding Academic Research Consortium Consensus Report
5小时前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
7小时前
已完结
Correction to Lancet Oncol 2023; 24: 1181-95
7小时前
已关闭
A comparison of the efficacy and safety of inhaled corticosteroids in asthma
1个月前
已完结
Hypothermia during CRRT, a comparative analysis
2个月前
已完结
Body temperature trends of critically Ill patients on continuous renal replacement therapy: A single-center retrospective study
2个月前
已完结
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
2个月前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
2个月前
已完结
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study
3个月前
已完结
皖公网安备34019202002308
